Treatment strategies for Hodgkin's disease.

G. Bonadonna, A. Santoro, S. Viviani, P. Valagussa

Research output: Contribution to journalArticle

Abstract

Over the past 2 decades, treatment of Hodgkin's disease has evolved considerably through innovations in the management of various stages. The impact of various treatments on the 5-, 10-, and 15-year results is being balanced against delayed morbidity, such as organ damage and second malignancies, produced by the intensity of therapy or the prolonged delivery of given drugs. The results of clinical trials performed during the past decade have allowed us to reconsider the various prognostic variables that can be used in the treatment strategy. The major unfavorable prognostic factors are represented by bulky disease, multiple extranodal sites, systemic B symptoms, age greater than 60 years, lymphocyte-depleted histology, male sex, and progressive disease during chemotherapy. In patients with early disease after surgical staging, the aim of current therapy is to provide a high cure rate within a short period and with limited morbidity. In patients with advanced Hodgkin's disease, the treatment strategy is to achieve durable complete remission in most cases through effective, full-dose, multidrug regimens at the expense of acceptable morbidity. Subtotal or total nodal radiotherapy (RT) induces a 10-year cure rate ranging from 70% to 85% in stages I and II with no bulky lymphoma. In patients with bulky disease and all three systemic symptoms, comparable results can be achieved with primary chemotherapy followed by RT. Currently, stages IIIA and IIIB disease are often managed with combined treatment modalities, although comparable results can be obtained with intensive chemotherapy alone.(ABSTRACT TRUNCATED AT 250 WORDS)

Original languageEnglish
Pages (from-to)51-57
Number of pages7
JournalSeminars in Hematology
Volume25
Issue number2 Suppl 2
Publication statusPublished - Apr 1988

Fingerprint

Hodgkin Disease
Morbidity
Drug Therapy
Therapeutics
Radiotherapy
Second Primary Neoplasms
Lymphoma
Histology
Clinical Trials
Lymphocytes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology

Cite this

Bonadonna, G., Santoro, A., Viviani, S., & Valagussa, P. (1988). Treatment strategies for Hodgkin's disease. Seminars in Hematology, 25(2 Suppl 2), 51-57.

Treatment strategies for Hodgkin's disease. / Bonadonna, G.; Santoro, A.; Viviani, S.; Valagussa, P.

In: Seminars in Hematology, Vol. 25, No. 2 Suppl 2, 04.1988, p. 51-57.

Research output: Contribution to journalArticle

Bonadonna, G, Santoro, A, Viviani, S & Valagussa, P 1988, 'Treatment strategies for Hodgkin's disease.', Seminars in Hematology, vol. 25, no. 2 Suppl 2, pp. 51-57.
Bonadonna G, Santoro A, Viviani S, Valagussa P. Treatment strategies for Hodgkin's disease. Seminars in Hematology. 1988 Apr;25(2 Suppl 2):51-57.
Bonadonna, G. ; Santoro, A. ; Viviani, S. ; Valagussa, P. / Treatment strategies for Hodgkin's disease. In: Seminars in Hematology. 1988 ; Vol. 25, No. 2 Suppl 2. pp. 51-57.
@article{3adb7c52c4914d29b52b403b3b44bad5,
title = "Treatment strategies for Hodgkin's disease.",
abstract = "Over the past 2 decades, treatment of Hodgkin's disease has evolved considerably through innovations in the management of various stages. The impact of various treatments on the 5-, 10-, and 15-year results is being balanced against delayed morbidity, such as organ damage and second malignancies, produced by the intensity of therapy or the prolonged delivery of given drugs. The results of clinical trials performed during the past decade have allowed us to reconsider the various prognostic variables that can be used in the treatment strategy. The major unfavorable prognostic factors are represented by bulky disease, multiple extranodal sites, systemic B symptoms, age greater than 60 years, lymphocyte-depleted histology, male sex, and progressive disease during chemotherapy. In patients with early disease after surgical staging, the aim of current therapy is to provide a high cure rate within a short period and with limited morbidity. In patients with advanced Hodgkin's disease, the treatment strategy is to achieve durable complete remission in most cases through effective, full-dose, multidrug regimens at the expense of acceptable morbidity. Subtotal or total nodal radiotherapy (RT) induces a 10-year cure rate ranging from 70{\%} to 85{\%} in stages I and II with no bulky lymphoma. In patients with bulky disease and all three systemic symptoms, comparable results can be achieved with primary chemotherapy followed by RT. Currently, stages IIIA and IIIB disease are often managed with combined treatment modalities, although comparable results can be obtained with intensive chemotherapy alone.(ABSTRACT TRUNCATED AT 250 WORDS)",
author = "G. Bonadonna and A. Santoro and S. Viviani and P. Valagussa",
year = "1988",
month = "4",
language = "English",
volume = "25",
pages = "51--57",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "2 Suppl 2",

}

TY - JOUR

T1 - Treatment strategies for Hodgkin's disease.

AU - Bonadonna, G.

AU - Santoro, A.

AU - Viviani, S.

AU - Valagussa, P.

PY - 1988/4

Y1 - 1988/4

N2 - Over the past 2 decades, treatment of Hodgkin's disease has evolved considerably through innovations in the management of various stages. The impact of various treatments on the 5-, 10-, and 15-year results is being balanced against delayed morbidity, such as organ damage and second malignancies, produced by the intensity of therapy or the prolonged delivery of given drugs. The results of clinical trials performed during the past decade have allowed us to reconsider the various prognostic variables that can be used in the treatment strategy. The major unfavorable prognostic factors are represented by bulky disease, multiple extranodal sites, systemic B symptoms, age greater than 60 years, lymphocyte-depleted histology, male sex, and progressive disease during chemotherapy. In patients with early disease after surgical staging, the aim of current therapy is to provide a high cure rate within a short period and with limited morbidity. In patients with advanced Hodgkin's disease, the treatment strategy is to achieve durable complete remission in most cases through effective, full-dose, multidrug regimens at the expense of acceptable morbidity. Subtotal or total nodal radiotherapy (RT) induces a 10-year cure rate ranging from 70% to 85% in stages I and II with no bulky lymphoma. In patients with bulky disease and all three systemic symptoms, comparable results can be achieved with primary chemotherapy followed by RT. Currently, stages IIIA and IIIB disease are often managed with combined treatment modalities, although comparable results can be obtained with intensive chemotherapy alone.(ABSTRACT TRUNCATED AT 250 WORDS)

AB - Over the past 2 decades, treatment of Hodgkin's disease has evolved considerably through innovations in the management of various stages. The impact of various treatments on the 5-, 10-, and 15-year results is being balanced against delayed morbidity, such as organ damage and second malignancies, produced by the intensity of therapy or the prolonged delivery of given drugs. The results of clinical trials performed during the past decade have allowed us to reconsider the various prognostic variables that can be used in the treatment strategy. The major unfavorable prognostic factors are represented by bulky disease, multiple extranodal sites, systemic B symptoms, age greater than 60 years, lymphocyte-depleted histology, male sex, and progressive disease during chemotherapy. In patients with early disease after surgical staging, the aim of current therapy is to provide a high cure rate within a short period and with limited morbidity. In patients with advanced Hodgkin's disease, the treatment strategy is to achieve durable complete remission in most cases through effective, full-dose, multidrug regimens at the expense of acceptable morbidity. Subtotal or total nodal radiotherapy (RT) induces a 10-year cure rate ranging from 70% to 85% in stages I and II with no bulky lymphoma. In patients with bulky disease and all three systemic symptoms, comparable results can be achieved with primary chemotherapy followed by RT. Currently, stages IIIA and IIIB disease are often managed with combined treatment modalities, although comparable results can be obtained with intensive chemotherapy alone.(ABSTRACT TRUNCATED AT 250 WORDS)

UR - http://www.scopus.com/inward/record.url?scp=0023986695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023986695&partnerID=8YFLogxK

M3 - Article

C2 - 3041600

AN - SCOPUS:0023986695

VL - 25

SP - 51

EP - 57

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 2 Suppl 2

ER -